Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets
Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023and Expected Milestones in 2024CARDIFF, United Kingdom, Jan. 22, 2024 (GLOBE NEWSWIRE) – Biodexa
These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory
Join Our Market Watch Newsletter!
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!
Start typing to search
To view TrendSpider's complete data, please log into your TrendSpider account.